Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: milestone -

Re: milestone - emit 13-G

in response to by
posted on Jan 20, 2008 02:06PM

SEC regulations require that venture funds and others who purchase privately-issued securities of a publicly-trade company must file a Schedule 13-G with the SEC if the fund and related persons hold in excess of 5% of the outstanding shares following an initial public offering (IPO) of the company. The Schedule 13-G must be filed by February 14th of the year following the year of the IPO. This Schedule also must be updated annually if there have been purchases, sales or distributions by the fund or related parties. The Schedule is filed on behalf of the fund or affiliated funds, the general partner entities, and each individual general partner.

 

 http://library.findlaw.com/1997/Feb/9/130683.html

 

 

Be well

Share
New Message
Please login to post a reply